Join the WHO Programme for International Drug Monitoring
Find out more about what it means for a country to be a full member of the WHO Programme and the steps needed to join.
This is a brief step-by-step description of the official requirements for joining the WHO Programme.
A guide is accessible here
- Familiarity with the standard methodology of spontaneous monitoring and reporting is essential. A country joining the WHO Programme must have a system in place for the collection of individual case safety reports (ICSRs). The national programme requires funding to ensure provision of staff, technical facilities and continuity of operation.
- A national pharmacovigilance centre for monitoring medicines must be designated and recognised by the ministry of health (or equivalent). Only WHO member states can join the WHO Programme for International Drug Monitoring.
- Technical competence is needed to meet reporting requirements to WHO. The national drug monitoring programme must demonstrate that it is capable of submitting case reports in the required format.
- Individual case safety reports submitted to the WHO database, VigiBase, must be freely available for analysis by member country investigators, according to WHO policy.
- A formal application to be admitted as a member of the WHO Programme has to be sent to WHO Headquarters, Geneva, by the competent health authority of the country. The application should identify the institution and responsible person representing the country as a national centre. A country is an associate member from the time the formal membership application is received. A sample of at least 20 ICSRs collected should be submitted to UMC before full membership is considered.
*To start as an associate member not all of the above requirements need to be fulfilled, please contact email@example.com for more information.
Last modified on: November 10, 2020